Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS

NCT03000439 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03000439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03000439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2018
Completion date
March 27, 2024
Enrollment
100 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis juvenile idiopathic